Hepatocellular carcinoma. An overview

Motola-Kuba, Daniel; Zamora-Valdés, Daniel; Uribe, Misael; Méndez-Sánchez, Nahúm

doi:10.1016/s1665-2681(19)32034-4

Cited by 130 publications

(72 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its incidence has increased dramatically in the US as a result of the current hepatitis C epidemic, and is expected to continue to do so over the next 2 decades [1,3]. Hepatitis B virus, hepatitis C virus, and chronic heavy alcohol use leading to cirrhosis remain the most important predisposing factors [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Liver Transplantation, Liver Resection, and Transarterial Chemoembolization for Hepatocellular Carcinoma in Cirrhosis: Which Is the Best Oncological Approach?

et al. 2008

View full text Add to dashboard Cite

The aim of the study was to evaluate our institutional experience with monotherapies for hepatocellular carcinoma (HCC) in the setting of cirrhosis. A retrospective cohort study was carried out at the tertiary care academic referral center and involved 185 consecutive HCC patients with cirrhosis and no previous treatment who underwent resection (n = 61), transarterial chemoembolization (TACE) (n = 64), or liver transplantation (LT) (n = 60). Long-term survival and survival according to the Milan criteria were the main outcomes measured. Median survival after resection, TACE, and LT was 11, 14, and 23 months, respectively. Five-year cumulative survival after resection, TACE, and LT was 23, 10, and 59%, respectively (P = 0.001). Five-year cumulative disease-free survival after resection and LT was 15% and 77%, respectively (P = 0.002). The presence of complications in the resection group (P = 0.004), MELD score (P = 0.0003), and maximum tumor diameter (P = 0.05) in the TACE group, and tumor grade (P = 0.01) and complications (P = 0.004) in the LT group were found to be independent predictors of survival. Five-year survival for patients within the Milan criteria after resection, TACE, and LT was 26, 37, and 66%, respectively. Five-year survival for patients outside the Milan criteria for patients undergoing LT was 53%. The results suggest that LT represents the best oncological treatment option for patients with HCC in the setting of cirrhosis, even for those beyond the Milan criteria. Considering the scarcity of available organs, liver resection remains the best alternative option. TACE remains a potential therapy in patients within the Milan criteria, where it may be more beneficial than resection.

show abstract

Section: Introductionmentioning

confidence: 99%

Liver Transplantation, Liver Resection, and Transarterial Chemoembolization for Hepatocellular Carcinoma in Cirrhosis: Which Is the Best Oncological Approach?

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Hepatocellular carcinoma (HCC) is the fifth most common cause of mortality from cancer worldwide and is responsible for about one million deaths yearly [1,2]. The number of cases of HCC will rise dramatically over the next 10-15 years in North America because of the high prevalence of chronic hepatitis infections [3].…”

Section: Introductionmentioning

confidence: 99%

Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization

Vossen

Buijs

Syed

et al. 2008

Clin Exp Metastasis

View full text Add to dashboard Cite

show abstract

“…Studies of the effect of hepatitis viruses [1][2][3][4][5], fatty liver disease [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20], and cirrhosis [1][2][3][4][5][6][7][21][22][23][24][25] on patient survival have been performed, usually as evaluations of a single disease entity or, in the case of cirrhosis, as the risk of death within a few months. It has been suggested that in some circumstances patients with more than one hepatic disease have an increased risk of death beyond patients with a single disease [13,14,25].…”

Section: Introductionmentioning

confidence: 99%

Increased Age, Male Gender, and Cirrhosis, but Not Steatosis or a Positive Viral Serology, Negatively Impact the Life Expectancy of Patients who Undergo Liver Biopsy

et al. 2007

View full text Add to dashboard Cite

Most survival studies of chronic liver disease avoid including more than one condition, often present in patients with liver disease; survival analysis of patients with liver disease in general was undertaken. Over a 9-year period, the survival experience of 365 patients who underwent liver biopsy, with a median follow-up of 3 years, was assessed. Log rank tests and Cox regression were used to evaluate risk factors. The Flemington-Harrington G(rho) family of tests compared the number of deaths expected in the U.S. population in general, adjusted for age, sex, and year of biopsy, to the observed number of deaths in the patients with cirrhosis and to the observed number of deaths in patients without cirrhosis. Twenty-two (6%) patients died. Cirrhosis (HR = 2.9; 95% c.i.: 1.2-6.7), male sex (HR = 2.7; 95% c.i.: 1.1-6.6), and an additional 20 years of age at biopsy (HR = 2.9; 95% c.i:. 1.4-6.2) each negatively impacted survival. Patients with cirrhosis experienced 4.58 times the number of expected deaths (p < 0.00001). Patients without cirrhosis experienced 1.66 times the number of expected deaths (p = 0.15). Steatosis and a positive viral serology did not increase the risk of death. Male gender, increased age, and cirrhosis increased the risk of death; increased steatosis and positive viral serologic studies did not.

show abstract

Hepatocellular carcinoma. An overview

Cited by 130 publications

References 52 publications

Liver Transplantation, Liver Resection, and Transarterial Chemoembolization for Hepatocellular Carcinoma in Cirrhosis: Which Is the Best Oncological Approach?

Liver Transplantation, Liver Resection, and Transarterial Chemoembolization for Hepatocellular Carcinoma in Cirrhosis: Which Is the Best Oncological Approach?

Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization

Increased Age, Male Gender, and Cirrhosis, but Not Steatosis or a Positive Viral Serology, Negatively Impact the Life Expectancy of Patients who Undergo Liver Biopsy

Contact Info

Product

Resources

About